Physician profile
Benjamin N Stein
NPI 1245402460
$3,693.87
in general payments reported to CMS, 2019-2025
15 companies · $880 in 2025
The $880 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2022: $313 · 2023: $479 · 2024: $903 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.66 | 2022-2025 | Skyrizi, Linzess, Viberzi |
| The Institute of Musculoskeletal Science and Education | $1,000.00 | 2019 | |
| Janssen Biotech, INC. | $226.31 | 2022-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $189.65 | 2023-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.11 | 2023-2025 | Xifaxan |
| Camber Spine Technologies LLC | $118.11 | 2019 | |
| Phathom Pharmaceuticals, INC. | $106.57 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $104.64 | 2024-2025 | |
| Lilly USA, LLC | $101.01 | 2025 | Omvoh |
| Gilead Sciences, INC. | $97.20 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.79 | 2024-2025 | Entyvio, Gattex |
| Genzyme Corporation | $67.67 | 2023-2025 | |
| Madrigal Pharmaceuticals | $61.57 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $60.09 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $24.49 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.